TC-510 (Not yet branded)
Other Medications
Description
TC-510 is an antibody-drug conjugate that targets mesothelin-expressing tumors, including colorectal cancer. This therapeutic combines a monoclonal antibody that specifically binds to mesothelin with a cytotoxic payload to deliver targeted chemotherapy directly to cancer cells. The drug is designed to treat advanced mesothelin-expressing cancers where mesothelin overexpression occurs.
Mechanism of Action
TC-510 works by binding to mesothelin, a glycoprotein that is overexpressed in various solid tumors including some colorectal cancers. Upon binding to mesothelin on the cancer cell surface, the antibody-drug conjugate is internalized, releasing its cytotoxic payload in
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.